

# Nancy E Davidson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11116557/publications.pdf>

Version: 2024-02-01

235  
papers

45,683  
citations

4146

87  
h-index

1825

210  
g-index

243  
all docs

243  
docs citations

243  
times ranked

37325  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. New England Journal of Medicine, 2005, 353, 1673-1684.	27.0	4,956
2	Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. New England Journal of Medicine, 2007, 357, 2666-2676.	27.0	2,865
3	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223.	1.2	2,805
4	A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. New England Journal of Medicine, 2003, 349, 1793-1802.	27.0	1,723
5	Estrogen Carcinogenesis in Breast Cancer. New England Journal of Medicine, 2006, 354, 270-282.	27.0	1,531
6	Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of Clinical Oncology, 2003, 21, 1431-1439.	1.6	1,464
7	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546.	1.2	1,449
8	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncology, The, 2010, 11, 55-65.	10.7	1,252
9	Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genetics, 1994, 7, 536-540.	21.4	1,112
10	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology, 2014, 32, 2959-2966.	1.6	1,080
11	Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. Journal of the National Cancer Institute, 2005, 97, 1262-1271.	6.3	1,048
12	Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. New England Journal of Medicine, 2008, 358, 1663-1671.	27.0	855
13	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology, 2015, 33, 2563-2577.	1.6	783
14	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 2014, 32, 3744-3752.	1.6	771
15	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2014, 32, 2255-2269.	1.6	661
16	American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer. Journal of Clinical Oncology, 2010, 28, 3784-3796.	1.6	655
17	Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology, 2011, 29, 3366-3373.	1.6	646
18	Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. New England Journal of Medicine, 2015, 372, 436-446.	27.0	588

#	ARTICLE	IF	CITATIONS
19	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016, 34, 2925-2934.	1.6	538
20	Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 961-965.	1.6	517
21	Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1231-1238.	1.6	485
22	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	27.0	448
23	A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. <i>Journal of the National Cancer Institute</i> , 2013, 105, 701-710.	6.3	442
24	HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 3032-3038.	1.6	429
25	Expression of Transforming Growth Factor $\beta$ and its Messenger Ribonucleic Acid in Human Breast Cancer: Its Regulation by Estrogen and its Possible Functional Significance. <i>Molecular Endocrinology</i> , 1988, 2, 543-555.	3.7	413
26	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 423-438.	1.6	384
27	Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831. <i>Journal of the National Cancer Institute</i> , 2002, 94, 855-857.	6.3	374
28	Anticancer activities of novel chalcone and bis-chalcone derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 3491-3495.	3.0	351
29	Local Excision Alone Without Irradiation for Ductal Carcinoma In Situ of the Breast: A Trial of the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 5319-5324.	1.6	346
30	Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. <i>Lancet</i> , The, 2001, 357, 1335-1336.	13.7	324
31	Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. <i>Journal of Clinical Oncology</i> , 2008, 26, 4063-4071.	1.6	312
32	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2078-2099.	1.6	303
33	Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1013-1021.	4.1	289
34	Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. <i>Carcinogenesis</i> , 2007, 28, 1485-1490.	2.8	283
35	Design, Synthesis, and Evaluation of Novel Boronic-Chalcone Derivatives as Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2813-2815.	6.4	281
36	Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2013, 31, 2942-2962.	1.6	279

#	ARTICLE	IF	CITATIONS
37	Epidermal Growth Factor Receptor Gene Expression in Estrogen Receptor-Positive and Negative Human Breast Cancer Cell Lines. <i>Molecular Endocrinology</i> , 1987, 1, 216-223.	3.7	258
38	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. <i>Journal of Clinical Oncology</i> , 2016, 34, 1689-1701.	1.6	243
39	American Society of Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance Guidelines. <i>Journal of Clinical Oncology</i> , 1999, 17, 1080-1080.	1.6	237
40	Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4491-4497.	1.6	228
41	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3938-3944.	1.6	223
42	Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Nodeâ€“Positive, Steroid Hormone Receptorâ€“Positive Breast Cancer: Results From INT 0101 (E5188). <i>Journal of Clinical Oncology</i> , 2005, 23, 5973-5982.	1.6	221
43	Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196. <i>Journal of Clinical Oncology</i> , 2004, 22, 4683-4690.	1.6	218
44	Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factorâ€“Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation. <i>Journal of Clinical Oncology</i> , 2009, 27, 5911-5918.	1.6	217
45	<i>HER2</i> and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4307-4315.	1.6	216
46	Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. <i>Journal of Clinical Oncology</i> , 2008, 26, 2473-2481.	1.6	212
47	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2â€“Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329.	1.6	210
48	Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 175-187.	2.5	199
49	Restoration of Tamoxifen Sensitivity in Estrogen Receptorâ€“Negative Breast Cancer Cells: Tamoxifen-Bound Reactivated ER Recruits Distinctive Corepressor Complexes. <i>Cancer Research</i> , 2006, 66, 6370-6378.	0.9	197
50	Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases. <i>Clinical Cancer Research</i> , 2008, 14, 1938-1946.	7.0	193
51	MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv073-djv073.	6.3	189
52	The biology of breast carcinoma. <i>Cancer</i> , 2003, 97, 825-833.	4.1	181
53	Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. <i>Journal of Clinical Oncology</i> , 2008, 26, 1948-1955.	1.6	176
54	Obesity at diagnosis is associated with inferior outcomes in hormone receptorâ€“positive operable breast cancer. <i>Cancer</i> , 2012, 118, 5937-5946.	4.1	174

#	ARTICLE	IF	CITATIONS
55	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2353-2360.	1.6	167
56	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1130-1137.	7.0	166
57	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2100-2108.	1.6	165
58	The loss of estrogen and progesterone receptor gene expression in human breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1998, 3, 85-94.	2.7	160
59	A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor 1± (ER) in ER negative human breast cancer cells in combination with 5-aza 2â€²-deoxycytidine. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 177-186.	2.5	160
60	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	10.7	153
61	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. <i>Oncogene</i> , 2019, 38, 390-405.	5.9	149
62	Release of Methyl CpG Binding Proteins and Histone Deacetylase 1 from the Estrogen Receptor 1± (ER) Promoter upon Reactivation in ER-Negative Human Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2005, 19, 1740-1751.	3.7	148
63	Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. <i>Cancer Biology and Therapy</i> , 2007, 6, 64-69.	3.4	143
64	Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2008, 6, 873-883.	3.4	143
65	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2736-2740.	1.6	141
66	Intrinsic Subtype Switching and Acquired <i>ERBB2</i> / <i>HER2</i> Amplifications and Mutations in Breast Cancer Brain Metastases. <i>JAMA Oncology</i> , 2017, 3, 666.	7.1	135
67	Role of Estrogen Receptor Gene Demethylation and DNA Methyltransferase-DNA Adduct Formation in 5-Aza-2â€²-deoxycytidine-induced Cytotoxicity In Human Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 32260-32266.	3.4	132
68	Transforming Cancer Prevention through Precision Medicine and Immune-oncology. <i>Cancer Prevention Research</i> , 2016, 9, 2-10.	1.5	130
69	Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. <i>Journal of Clinical Oncology</i> , 2007, 25, 2006-2011.	1.6	126
70	Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid. <i>Clinical Cancer Research</i> , 2006, 12, 3306-3310.	7.0	122
71	Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response. <i>Cancer Research</i> , 2014, 74, 1463-1474.	0.9	122
72	Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 581-592.	2.5	121

#	ARTICLE	IF	CITATIONS
73	Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 3700-3704.	1.6	120
74	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 3152-3165.	1.6	117
75	Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. <i>Breast Cancer Research</i> , 2017, 19, 60.	5.0	116
76	Epigenetics in breast cancer: what's new?. <i>Breast Cancer Research</i> , 2011, 13, 225.	5.0	114
77	Increased Protein Stability Causes DNA Methyltransferase 1 Dysregulation in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2005, 280, 18302-18310.	3.4	113
78	Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 777-789.	2.5	110
79	Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. <i>Clinical Cancer Research</i> , 2015, 21, 5082-5091.	7.0	106
80	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacididine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , 2017, 23, 2691-2701.	7.0	106
81	Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2115-2122.	1.6	104
82	Spermine Oxidase SMO(PAOh1), Not N1-Acetyl/polyamine Oxidase PAO, Is the Primary Source of Cytotoxic H2O2 in Polyamine Analogue-treated Human Breast Cancer Cell Lines. <i>Journal of Biological Chemistry</i> , 2005, 280, 39843-39851.	3.4	99
83	Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. <i>Carcinogenesis</i> , 2013, 34, 1196-1207.	2.8	98
84	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2736-2741.	7.1	95
85	Estrogen Receptor Î± Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death. <i>Cancer Research</i> , 2007, 67, 5337-5344.	0.9	94
86	Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197. <i>Journal of Clinical Oncology</i> , 2008, 26, 4092-4099.	1.6	93
87	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2804-2807.	1.6	93
88	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 295-300.	2.5	89
89	Race and Hormone Receptorâ€“Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 406-414.	6.3	89
90	Primary Systemic Therapy in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 1558-1569.	1.6	84

#	ARTICLE	IF	CITATIONS
91	Specific Inhibition of DNMT1 by Antisense Oligonucleotides Induces Re-expression of Estrogen Receptor $\alpha$ (ER) in ER-negative Human Breast Cancer Cell Lines. <i>Cancer Biology and Therapy</i> , 2003, 2, 552-556.	3.4	84
92	Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3051-3057.	1.6	83
93	A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5922-8.	7.0	79
94	Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. <i>Amino Acids</i> , 2012, 42, 887-898.	2.7	78
95	A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF- $\alpha$ Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 949-961.	3.4	77
96	Molecular mechanisms of polyamine analogs in cancer cells. <i>Anti-Cancer Drugs</i> , 2005, 16, 229-241.	1.4	73
97	Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 585-591.	2.5	73
98	Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5362-5369.	7.0	73
99	Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. <i>Clinical Cancer Research</i> , 2017, 23, 43-51.	7.0	73
100	Epigenetic Regulation as a New Target for Breast Cancer Therapy. <i>Cancer Investigation</i> , 2007, 25, 659-665.	1.3	72
101	Epigenetic Reprogramming of <i>HOXC10</i> in Endocrine-Resistant Breast Cancer. <i>Science Translational Medicine</i> , 2014, 6, 229ra41.	12.4	72
102	Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2001, 6, 183-192.	2.7	71
103	A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6277-6283.	7.0	69
104	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 683-692.	2.5	69
105	Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. <i>Carcinogenesis</i> , 2010, 31, 382-387.	2.8	68
106	Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. <i>Journal of the National Cancer Institute</i> , 2012, 104, 159-162.	6.3	68
107	<i>C-MYC</i> Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 651-659.	1.6	64
108	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. <i>Nature Communications</i> , 2019, 10, 5114.	12.8	64

#	ARTICLE	IF	CITATIONS
109	Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. <i>Molecular Oncology</i> , 2012, 6, 222-236.	4.6	63
110	Practical Approach to Triple-Negative Breast Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, 293-300.	2.5	63
111	Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 907-914.	2.5	62
112	The search for ESR1 mutations in breast cancer. <i>Nature Genetics</i> , 2013, 45, 1415-1416.	21.4	62
113	Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 443-451.	2.5	61
114	Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 2612-2635.	1.6	60
115	American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3939-3942.	1.6	59
116	Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. <i>Cancer Research</i> , 2018, 78, 6209-6222.	0.9	58
117	A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 915-924.	2.5	57
118	The follow-up of breast cancer. <i>Seminars in Oncology</i> , 2003, 30, 338-348.	2.2	56
119	The molecular landscape of premenopausal breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 104.	5.0	56
120	WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. <i>Breast Cancer Research</i> , 2016, 18, 92.	5.0	56
121	Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth. <i>Journal of Biological Chemistry</i> , 2018, 293, 1120-1137.	3.4	55
122	HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. <i>International Journal of Cancer</i> , 2018, 143, 1388-1401.	5.1	54
123	Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial. <i>Clinical Cancer Research</i> , 2013, 19, 1281-1289.	7.0	52
124	Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 99-108.	2.5	52
125	A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. <i>Clinical Cancer Research</i> , 2003, 9, 2769-77.	7.0	52
126	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 505.	7.1	51

#	ARTICLE	IF	CITATIONS
127	Multiparametric Magnetic Resonance Imaging, Spectroscopy and Multinuclear ( <sup>23</sup> Na) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer. <i>Academic Radiology</i> , 2010, 17, 1477-1485.	2.5	49
128	Methyl-group dietary intake and risk of breast cancer among African-American women: a case-control study by methylation status of the estrogen receptor alpha genes. <i>Cancer Causes and Control</i> , 2003, 14, 827-836.	1.8	48
129	A metastasis biomarker (MetaSite Breast <sup>®</sup> Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 42.	5.2	48
130	Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831. <i>Cancer</i> , 2013, 119, 2675-2682.	4.1	46
131	PI3 Kinase Activation and Response to Trastuzumab Therapy: What's new with Herceptin Resistance?. <i>Cancer Cell</i> , 2007, 12, 297-299.	16.8	45
132	Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. <i>Proteomics</i> , 2010, 10, 1029-1039.	2.2	43
133	Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). <i>British Journal of Cancer</i> , 2015, 113, 1651-1657.	6.4	43
134	Sixteen-Week Dose-Intense Chemotherapy in the Adjuvant Treatment of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 1990, 82, 570-574.	6.3	42
135	Multiparametric and Multinuclear Magnetic Resonance Imaging of Human Breast Cancer: Current Applications. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 543-550.	1.9	41
136	Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 57-66.	2.5	40
137	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	1.6	40
138	Protein Phosphatase 2A Regulates Estrogen Receptor $\beta$ (ER) Expression through Modulation of ER mRNA Stability. <i>Journal of Biological Chemistry</i> , 2005, 280, 29519-29524.	3.4	39
139	Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. <i>Oncogene</i> , 1998, 17, 577-583.	5.9	37
140	Polyamine Analogues Down-regulate Estrogen Receptor $\beta$ Expression in Human Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 19055-19063.	3.4	37
141	What Is the Role of Ovarian Ablation in the Management of Primary and Metastatic Breast Cancer Today?. <i>Oncologist</i> , 2004, 9, 507-517.	3.7	36
142	AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health. <i>Cancer Prevention Research</i> , 2018, 11, 735-778.	1.5	36
143	Regulation of Estrogen Receptor $\beta$ Function in Breast Cancer. <i>Critical Reviews in Oncogenesis</i> , 1997, 8, 29-46.	0.4	36
144	Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells. <i>Oncogene</i> , 1999, 18, 7453-7461.	5.9	35

#	ARTICLE	IF	CITATIONS
145	The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1067-1081.	2.3	34
146	Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. <i>Carcinogenesis</i> , 2013, 34, 2587-2592.	2.8	34
147	Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. <i>Oncotarget</i> , 2017, 8, 81737-81753.	1.8	34
148	THE BIOLOGY OF BREAST CANCER. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 311-332.	2.2	33
149	Sometimes a Great Notion—An Assessment of Neoadjuvant Systemic Therapy for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 159-161.	6.3	33
150	Regulation of Polyamine Analogue Cytotoxicity by c-Jun in Human MDA-MB-435 Cancer Cells. <i>Molecular Cancer Research</i> , 2004, 2, 81-88.	3.4	32
151	Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. <i>Cancer Biology and Therapy</i> , 2004, 3, 1304-1312.	3.4	30
152	Monoclonal Antibody Cocktail as an Enrichment Tool for Acetylome Analysis. <i>Analytical Chemistry</i> , 2011, 83, 3623-3626.	6.5	30
153	Novel Insight into KLF4 Proteolytic Regulation in Estrogen Receptor Signaling and Breast Carcinogenesis. <i>Journal of Biological Chemistry</i> , 2012, 287, 13584-13597.	3.4	30
154	A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. <i>Hormones and Cancer</i> , 2015, 6, 214-224.	4.9	30
155	AACR Cancer Progress Report 2016. <i>Clinical Cancer Research</i> , 2016, 22, S1-S137.	7.0	29
156	Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1005-1005.	1.6	28
157	Induction of spermidine/spermine N 1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N 1,N 11-diethylnorspermine. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 122-126.	2.3	27
158	Perspectives of Postmenopausal Breast Cancer Survivors on Adjuvant Endocrine Therapy-Related Symptoms. <i>Oncology Nursing Forum</i> , 2014, 41, 660-668.	1.2	27
159	Of Snail, mice, and women. <i>Cancer Cell</i> , 2005, 8, 173-174.	16.8	26
160	Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4008-4016.	7.0	26
161	Epigenetic reprogramming in breast cancer: From new targets to new therapies. <i>Annals of Medicine</i> , 2014, 46, 397-408.	3.8	26
162	Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1580-1583.	1.6	26

#	ARTICLE	IF	CITATIONS
163	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 501-504.	2.5	24
164	Integrated Proteomic and Metabolic Analysis of Breast Cancer Progression. <i>PLoS ONE</i> , 2013, 8, e76220.	2.5	24
165	Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7693-7700.	7.0	23
166	Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. <i>Breast</i> , 2013, 22, S165-S170.	2.2	23
167	Trastuzumab in breast cancer. <i>Oncology</i> , 2004, 18, 1117-28; discussion 1131-2, 1137-8.	0.5	23
168	Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. <i>Scientific Reports</i> , 2018, 8, 17313.	3.3	22
169	Adjuvant Hormonal Therapy for Premenopausal Women With Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 657-663.	2.2	21
170	Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy With Pegfilgrastim Support. <i>Journal of Clinical Oncology</i> , 2006, 24, 2392-2394.	1.6	21
171	Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831. <i>Clinical Cancer Research</i> , 2013, 19, 5798-5807.	7.0	21
172	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. <i>Breast Cancer Research</i> , 2015, 17, 133.	5.0	21
173	Epigenetics meets estrogen receptor: regulation of estrogen receptor by direct lysine methylation. <i>Endocrine-Related Cancer</i> , 2009, 16, 319-323.	3.1	20
174	Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7194-7203.	7.0	20
175	Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 311-321.	2.5	20
176	Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 23-32.	3.8	20
177	Aromatase inhibitors for breast cancer. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 8, 215-228.	5.7	19
178	Ovarian ablation as adjuvant therapy for breast cancer. <i>Seminars in Oncology</i> , 2001, 28, 322-331.	2.2	19
179	Expertise vs Evidence in Assessment of Breast Biopsies. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1109.	7.4	18
180	Role of p53/p21Waf1/Cip1 in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. <i>Cancer Biology and Therapy</i> , 2005, 4, 1006-1013.	3.4	17

#	ARTICLE	IF	CITATIONS
181	The silent estrogen receptor--can we make it speak?. Cancer Biology and Therapy, 2009, 8, 485-496.	3.4	17
182	Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene, 2015, 4, 129-141.	0.6	17
183	Hematopoietic growth factors: Personalization of risks and benefits. Molecular Oncology, 2012, 6, 237-241.	4.6	16
184	TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2012, 134, 751-757.	2.5	16
185	Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of <i>Igf1r</i> That Persists Long after Parturition. Cancer Prevention Research, 2015, 8, 1000-1009.	1.5	16
186	Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma. Scientific Reports, 2020, 10, 11487.	3.3	16
187	Feasibility Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2816-2822.	1.6	15
188	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Research and Treatment, 2011, 127, 153-162.	2.5	15
189	Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Breast, 2015, 24, S120-S125.	2.2	15
190	Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. Cellular and Molecular Life Sciences, 2014, 71, 1549.	5.4	14
191	Epigenetic Biomarkers and Breast Cancer: Cause for Optimism. Clinical Cancer Research, 2006, 12, 6591-6593.	7.0	12
192	What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. Current Oncology Reports, 2009, 11, 45-50.	4.0	12
193	Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells. Molecular Cancer Research, 2004, 2, 81-8.	3.4	12
194	Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Research and Treatment, 1993, 28, 277-284.	2.5	11
195	New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. Clinical Cancer Research, 2017, 23, 1126-1131.	7.0	11
196	Can Circulating Tumor Cells Predict Resistance in Metastatic Breast Cancer?. Clinical Cancer Research, 2015, 21, 2421-2423.	7.0	9
197	The regulation of estrogen receptor expression and function in human breast cancer. Cancer Treatment and Research, 1998, 94, 255-278.	0.5	9
198	Apoptosis in Hormone-Responsive Malignancies. Advances in Pharmacology, 1997, 41, 553-583.	2.0	8

#	ARTICLE	IF	CITATIONS
199	Plasma Matrix Metalloproteinases 7 and 9 in Patients with Metastatic Breast Cancer Treated with Marimastat or Placebo: Eastern Cooperative Oncology Group Trial E2196. <i>Clinical Breast Cancer</i> , 2006, 6, 525-529.	2.4	8
200	Silencing estrogen receptor $\beta$ in breast cancer cells. <i>Cancer Biology and Therapy</i> , 2006, 5, 848-849.	3.4	8
201	Use of SERMs for the Adjuvant Therapy of Early-Stage Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2001, 949, 80-88.	3.8	6
202	Still Waiting After 110 Years: The Optimal Use of Ovarian Ablation As Adjuvant Therapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4949-4951.	1.6	6
203	Targeting tumorigenicity of breast cancer stem-like cells using combination epigenetic therapy: something old and something new. <i>Journal of Thoracic Disease</i> , 2016, 8, 2971-2974.	1.4	6
204	The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility. <i>Clinical Cancer Research</i> , 2020, 26, 5543-5545.	7.0	6
205	Optimal adjuvant endocrine therapy for breast cancer. <i>Lancet Oncology</i> , The, 2021, 22, 1357-1358.	10.7	6
206	The maturation of medical oncology. <i>Lancet Oncology</i> , The, 2007, 8, 457-458.	10.7	5
207	The American Society of Clinical Oncology Cancer Foundation Grants Program: A 25-Year Report and a Look Toward the Future. <i>Journal of Clinical Oncology</i> , 2010, 28, 1616-1621.	1.6	5
208	Adjuvant Endocrine Therapy for Breast Cancer: Don't Ditch the Switch!. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1280-1282.	6.3	5
209	Should We Embrace or Ablate Our Urge to (Ovarian) Suppress?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3920-3922.	1.6	5
210	Searching for the IDEAL Duration of Adjuvant Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 6-8.	6.3	5
211	Inhibition of Histone Deacetylases. <i>Methods in Molecular Biology</i> , 2011, 791, 297-311.	0.9	5
212	HER2-targeted therapies: how far we've come--and where we're headed. <i>Oncology</i> , 2011, 25, 425-6.	0.5	5
213	Postoperative Endocrine Therapy for Invasive Breast Cancer. <i>Cancer Treatment and Research</i> , 2009, 151, 139-161.	0.5	4
214	Apoptosis and Breast Cancer. , 1999, , 291-303.		4
215	Deja Vu for Breast Cancer Two?. <i>Journal of the National Cancer Institute</i> , 2004, 96, 497-499.	6.3	3
216	Case 35-2005. <i>New England Journal of Medicine</i> , 2005, 353, 2177-2185.	27.0	3

#	ARTICLE	IF	CITATIONS
217	Treatment for Breast Cancer: Is Time Really of the Essence?. Journal of the National Cancer Institute, 2013, 105, 80-82.	6.3	3
218	Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?. Clinical Cancer Research, 2016, 22, 4963-4965.	7.0	3
219	The 21-gene recurrence score " biology remains at the forefront. Nature Reviews Clinical Oncology, 2016, 13, 470-472.	27.6	3
220	New findings about endocrine therapy for breast cancer. Breast, 2003, 12, 368-372.	2.2	2
221	How We Maintain Bone Health in Early-Stage Breast Cancer Patients on Aromatase Inhibitors. Journal of Oncology Practice, 2007, 3, 323-325.	2.5	2
222	Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era. Journal of the National Cancer Institute, 2019, 111, 641-643.	6.3	2
223	Reply to J.M. Guinebreiere and L. Arnould et al. Journal of Clinical Oncology, 2009, 27, 2734-2735.	1.6	1
224	Small Beginnings: Do They Matter? The Importance of Lymphovascular Invasion in Early Breast Cancer. Journal of the National Cancer Institute, 2009, 101, 698-699.	6.3	1
225	Conquering Metastatic Breast Cancer. Journal of Oncology Practice, 2016, 12, 11-12.	2.5	1
226	"Take two" The role of second opinions for breast biopsy specimens. BMJ, The, 2016, 353, i3256.	6.0	1
227	Optimal duration of trastuzumab for early HER2-positive breast cancer. Lancet, The, 2017, 389, 1167-1168.	13.7	1
228	Incident Cancer in Cancer Survivors" When Cancer Lurks in the Background. JAMA Oncology, 2018, 4, 836.	7.1	1
229	Gonadotropin-Releasing Hormone (GnRH) Agonists for Fertility Preservation: Is POEMS the Final Verse?. Journal of the National Cancer Institute, 2019, 111, 107-108.	6.3	1
230	Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. Cancer, 2020, 126, 5239-5246.	4.1	1
231	Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. Cancer Investigation, 2021, 39, 21-24.	1.3	1
232	Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought?. Journal of the National Cancer Institute, 2021, 113, 1444-1446.	6.3	1
233	What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. Current Breast Cancer Reports, 2009, 1, 42-47.	1.0	0
234	Reply to C. Shah et al. Journal of Clinical Oncology, 2016, 34, 1824-1825.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Epigenetic Regulation as a New Target for Breast Cancer Therapy. Translational Medicine Series, 2007, , 285-296.	0.0	0